23rd October 2024 (10 Topics)

Copy

1 Oct

2 Oct

3 Oct

4 Oct

5 Oct

7 Oct

8 Oct

9 Oct

10 Oct

11 Oct

12 Oct

14 Oct

15 Oct

16 Oct

17 Oct

18 Oct

19 Oct

21 Oct

22 Oct

23 Oct

24 Oct

Approval of Cobenfy for Schizophrenia

Context

In 2023, the U.S. Food and Drug Administration (FDA) approved a new medication called Cobenfy for the treatment of schizophrenia. This approval is significant as it introduces a novel approach to managing this serious mental health disorder, which affects about 1 in 100 people globally.

What is Cobenfy?

Cobenfy is a combination of two drugs: xanomeline and trospium chloride.
It works differently from traditional antipsychotic medications, which primarily target dopamine receptors in the brain.
Instead, Cobenfy targets cholinergic receptors, which are part of the parasympathetic nervous system.
This unique mechanism may help alleviate symptoms without the severe side effects often associated with older antipsychotic drugs.
The Role of Neurotransmitters
- Traditionally, the dopamine hypothesis has been used to explain schizophrenia, suggesting that overactivity of dopamine in the brain leads to symptoms. However, newer research points to a more complex interplay involving other neurotransmitters, such as glutamate.
- Xanomeline and Trospium
  - Xanomeline: This compound stimulates cholinergic receptors and has shown potential in improving various symptoms of schizophrenia. However, it previously faced setbacks due to side effects.
  - Trospium Chloride: This medication acts as an antimuscarinic agent, potentially reducing the side effects associated with xanomeline.
- Side Effects and Cost: Cobenfy has its own side effects, which may include: Nausea, Indigestion, Hypertension, Increased heart rate, Dizziness
- The monthly cost of Cobenfy is approximately USD 1,850, making it an expensive option for many patients.

Fact Box: Schizophrenia

Schizophrenia is a complex psychiatric disorder characterized by symptoms such as:
- Positive Symptoms: Delusions and hallucinations.
- Negative Symptoms: A lack of motivation, reduced emotional expression, and social withdrawal.
- Disorganized Symptoms: Confused speech and behavior.
The impact of schizophrenia is profound, leading to social isolation, stigma, and a significantly reduced life expectancy—often 13 to 15 years shorter than average. Individuals with schizophrenia also face a higher risk of suicide, with about 5% of patients taking their own lives.
Symptoms and Diagnosis: Schizophrenia typically manifests in late adolescence or early adulthood, with men generally experiencing symptoms in their early 20s and women in their mid- to late 40s. Early symptoms may include:
- Irritability
- Anxiety
- Social withdrawal
For diagnosis, symptoms are categorized into three groups:
- Positive Symptoms: Such as hallucinations and delusions.
- Negative Symptoms: Including a lack of emotional expression and reduced motivation.
- Disorganized Symptoms: Difficulties in speech and behavior.
Causes of Schizophrenia: Schizophrenia is considered a multifactorial disorder influenced by both genetic and environmental factors. Key insights include:
- Genetics: Numerous genes have been linked to schizophrenia risk. Unlike single-gene disorders, schizophrenia arises from the interplay of many genes, each contributing a small effect.
- Environmental Factors: Complications during pregnancy and birth can increase the risk of developing schizophrenia, especially when combined with genetic predispositions.

Over the borderline: On the India-China deal

International Relations India and its Neighbourhood

Berlin-Delhi Reconnection

International Relations Bilateral relations

The job crisis undermines state legitimacy

Economy Poverty and Unemployment

India-Russia’s ‘Deep-Rooted’ Ties

International Relations Bilateral relations

The Rise of Nuclear Power

Science & Technology Nuclear Technology

Kartarpur Sahib Corridor

Art and culture Religion

Chabahar Port deal

International Relations Bilateral relations

India launches fourth nuclear-powered submarine

Science & Technology Defence

New genus of jumping spiders ‘Tenkana’

Ecology and Environment Biodiversity

GS Analyst: Daily Current Affairs

23rd October 2024 (10 Topics)

Copy

Approval of Cobenfy for Schizophrenia

What is Cobenfy?

Fact Box: Schizophrenia

Still Have Questions?

GS Analyst: Daily Current Affairs

Approval of Cobenfy for Schizophrenia

What is Cobenfy?

Fact Box: Schizophrenia

Still Have Questions?

User Login

User Register

Forgot Password

Verify Your Mobile Number